Mayflower Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3,420
Closed -$338K 397
2024
Q3
$338K Sell
3,420
-128
-4% -$12.6K 0.05% 275
2024
Q2
$329K Buy
+3,548
New +$318K 0.05% 271
2021
Q1
Sell
-2,365
Closed -$333K 315
2020
Q4
$333K Buy
+2,365
New +$303K 0.06% 193

Other funds holding XBI

Mayflower Financial Advisors's XBI Position: Q4 2024 in Review

Mayflower Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 3,420 shares — an estimated $338K sold.

Mayflower Financial Advisors first reported a position in XBI in Q4 2020 and held it in 3 quarters. The position peaked at $338K in Q3 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Mayflower Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Mayflower Financial Advisors sold 3,420 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $338K.
  • Mayflower Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 3 quarters.
  • Mayflower Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $338K in Q3 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Mayflower Financial Advisors's 13F filing for Q4 2024, filed 22 Jan 2025.